PUBLIC DOCUMENTS


Meaning

Public documents are official records authenticated by public officers in their official capacity. These documents serve as reliable evidence in civil matters and are made accessible for public reference and use. They ensure transparency and accountability in governance by allowing the public to inspect and rely on them for legal and administrative purposes.

 

Characteristics of Public Documents

As established in Rangaraju vs. Kannayal and Ors., public documents have several defining characteristics. First, they must be prepared by a public servant while performing official duties. This ensures their authenticity and reliability. Second, these documents should be available for public reference and use, reflecting their public nature. Third, they must pass the test of publicity, meaning the public should have an interest in them and the right to verify their accuracy. If errors are identified, the public has the right to raise objections. Lastly, public documents grant the public the right to inspect and obtain certified copies by paying a prescribed fee, reinforcing their accessibility and evidentiary value.

 

Nature of Public Documents

Section 74 of the Indian Evidence Act categorizes certain documents as public. These include acts or records of acts performed by sovereign authorities, official bodies, tribunals, or public officers in their legislative, judicial, or executive capacities. Such documents may originate from India, the Commonwealth, or foreign nations. Additionally, public records of private documents, maintained by public offices, are also classified as public documents.

 

Types of Public Documents and Their Proof

Section 78 of the Indian Evidence Act specifies how different types of public documents can be proved. Acts, notifications, or orders are authenticated through certified records signed by departmental heads. Legislative proceedings are verified using officially published government records. Proclamations, orders, or regulations are evidenced by gazette notifications. For acts of foreign legislatures or executives, official journals or certified copies by legal keepers are used. Records maintained by municipal bodies are proven through published authoritative books. Documents from foreign countries must be certified by diplomatic agents, consuls, or notary publics, ensuring their credibility.

 

Proof of Contents of Public Documents

The contents of public documents are admissible in courts of law, and it is not necessary to produce the original document. Instead, certified copies, authenticated by the appropriate authority, suffice as evidence. This provision simplifies the evidentiary process while maintaining the integrity of the documents presented.

 

Certified Copies of Public Documents

According to Section 76, certified copies of public documents are authenticated reproductions, verified by a public officer with custody of the original document. These certified copies are legally valid and can be obtained by any individual upon payment of a prescribed fee. The certification process requires the officer to confirm in writing that the copy is a true reproduction, along with a date, official seal, and signature, ensuring its authenticity.

To obtain a certified copy, an individual must first request access to the document and pay the required fee. The certified copy, once prepared, includes a statement affirming its accuracy and bears the officer’s authentication. This process ensures that the document can be relied upon in legal and administrative matters.

 

Examples of Public Documents

Public documents include records such as school registers, census reports, and birth and death certificates maintained by municipal authorities. For instance, in Prem Chand Sao v State of Jharkhand, a school leaving certificate indicating a student’s age was deemed admissible without formal proof. Similarly, FIRs and charge sheets are recognized as public documents, as seen in Royal Sundaram Alliances vs D. Gunasekharan. Other examples include confessions recorded by magistrates, marriage registers (Seema vs Ashwin Kumar), sale or lease deeds (Gopinath Educational and Welfare Society v Rejendra Singh Shekhawat), and medico-legal reports (Dalip Kumar Alias Pinkie vs. State). These documents exemplify the wide range of records considered public under the law.

 

Documents That Are Not Public Documents

Not all documents created by or associated with public officers qualify as public documents. For example, income tax returns (Anwar Ali v Tafozal Ahmed), plaints or written statements filed in court (Gulab Chand v Sheo Karan Lal), and police panchanamas (Hardayal Haram Singh case) are not classified as public documents. Similarly, a doctor's certificate on the date of death (State v Bhola Pal) or a registered power of attorney does not meet the criteria to be considered public. These distinctions are crucial for understanding the evidentiary scope and limitations of public documents.

 

Conclusion

Public documents are indispensable in ensuring transparency, accountability, and reliability in legal and administrative matters. Authenticated by public officers, these records are admissible as evidence and are accessible for public inspection. They serve as a bridge between governance and public trust, offering a mechanism for verifying official actions and records. Certified copies further enhance their usability, making them integral to the functioning of legal systems and public administration. Unlike private documents, public documents are subject to greater scrutiny and enjoy specific evidentiary privileges, underscoring their vital role in civil society.

 

CASE ANALYSIS on Novozymes v. Assistant Controller of Patents & Designs

CASE ANALYSIS

Parties: Novozymes v. Assistant Controller of Patents & Designs

Bench: The Hon’ble Mr. Justice Senthilkumar Ramamoorthy

Case Number: CMA (PT) No. 33 of 2023

Citation: 2023 MHC 4261

 

Introduction

The case Novozymes v. Assistant Controller of Patents & Designs[1] revolves around an appeal against the rejection of a patent application by the Patent Office, Chennai. Novozymes sought to patent phytase variants with improved thermostability under Indian Patent Application No. 5326/CHENP/2008. The Assistant Controller rejected the application on grounds of Sections 3(d) and 3(e) of the Patents Act, 1970, asserting that the invention lacked significant enhancement of known efficacy and synergy among its composition. This case highlights critical interpretations of patent eligibility under Indian law, particularly for biochemical innovations.

 

Facts Of The Case

In Indian Patent Application No. 5326/CHENP/2008, Novozymes sought to patent an invention titled "Phytase Variants with Improved Thermostability." The invention involved modifying the amino acid sequence of phytase enzyme (SEQ ID NO:2) to create variants with enhanced thermostability, aiming to improve the enzyme’s ability to withstand high temperatures, particularly for industrial applications like pelletized animal feed. The variants included one to four amino acid alterations from a list of possible mutations, such as 4P, 46E, 52E, 53V, 76G, 107G, and others. Novozymes also provided a method to test thermostability by measuring the enzyme’s residual activity after incubating it at 60°C and 5°C, comparing it to the reference phytase SEQ ID NO:2. The enhanced thermostability was claimed to make these variants suitable for use at higher temperatures without denaturation, increasing their industrial utility.

In addition to the phytase variants, the application included composition claims (claims 8–11), which combined the thermostable phytase variants with fat-soluble and water-soluble vitamins and trace minerals to form animal feed additives intended to provide nutritional benefits.

However, the Assistant Controller of Patents & Designs rejected the application, arguing that the invention did not meet patentability requirements under Sections 3(d) and 3(e) of the Patents Act, 1970. Under Section 3(d), the Controller contended that the invention was merely a new form of a known substance (phytase) without significantly enhancing its efficacy. The Controller argued that enhanced thermostability did not improve phytase’s primary function—hydrolyzing phytate for phosphorus digestion—beyond what was already known. The composition claims (claims 8–11) were rejected under Section 3(e) as they were considered a mere admixture of known ingredients, without synergy or a novel interaction that would warrant patentability.

Novozymes filed an appeal, challenging the rejection. It argued that the enhanced thermostability of the variants represented a significant improvement in the enzyme's efficacy for industrial applications, especially in animal feed production. The company also contended that the composition claims involved novel combinations with potential synergistic effects. The appeal raised critical questions about the interpretation of Section 3(d) in the context of biochemicals like phytase and the applicability of Section 3(e) to compositions that utilized these innovations.[2]

 

Issues Raised

1.     Whether the term "known substance" under Section 3(d) of the Patents Act should be interpreted to include biochemical substances like phytase variants or is it limited to synthetic chemical substances.

2.     Whether the enhanced thermostability of the phytase variants constitutes a "significant enhancement" of the known efficacy of the enzyme under Section 3(d).

3.     Whether the composition claims (claims 8–11) are merely an admixture of known ingredients without the necessary synergy to be patentable under Section 3(e).

4.     Whether the combination of phytase variants with vitamins and minerals in the composition claims exhibits synergy beyond the sum of its parts, making it eligible for patent protection under Section 3(e).

 

Analysis Of The Issues Raised

1. Does "known substance" under Section 3(d) include biochemicals like phytase variants or is it limited to synthetic chemicals?

The term "known substance" under Section 3(d) raises questions about its scope—whether it applies only to synthetic chemicals or can extend to biochemicals. Section 3(d) prohibits patents for new forms of known substances unless they enhance efficacy, and its Explanation lists examples like salts, esters, and isomers, which are generally associated with synthetic chemicals.

In this case, the appellant argued that phytase, being a naturally occurring enzyme, should not be treated as a synthetic chemical and should not fall within the Explanation. The Court applied the ejusdem generis principle and found that the Explanation is indeed limited to synthetic chemicals. However, the broader substantive provision of Section 3(d), which excludes certain known substances, applies to all substances, including biochemicals like phytase.

The Court distinguished between synthetic and biochemical substances while ensuring that biochemicals still fall under the ambit of Section 3(d). This interpretation underscores the law’s intent to balance the exclusion of trivial inventions with the encouragement of innovation in biotechnology.

 

2. Does enhanced thermostability qualify as a "significant enhancement" of efficacy under Section 3(d)?

Efficacy under Section 3(d) depends on the context of the invention. For pharmaceuticals, the Supreme Court in Novartis AG v. Union of India held that efficacy refers to therapeutic efficacy. In this case, the appellant claimed that enhanced thermostability—a property allowing phytase to remain stable at high temperatures—improved the enzyme’s industrial utility in animal feed production.

The Assistant Controller argued that enhanced thermostability did not improve the enzyme’s primary function—catalyzing the hydrolysis of phytate. However, the Court noted that thermostability is a critical property for the enzyme's practical use in high-temperature environments like feed pelletization. Without this property, the enzyme would denature, losing its effectiveness in industrial applications.

The Court concluded that thermostability enhances the enzyme’s efficacy by expanding its utility in real-world conditions, even if it does not directly improve its enzymatic activity. This interpretation recognizes that efficacy is not limited to a substance’s core function but also includes enhancements that make it more applicable or valuable in practical settings.

 

3. Do the composition claims (claims 8–11) qualify as patentable under Section 3(e), or are they merely admixtures of known substances?

Section 3(e) excludes compositions from patentability if they are formed by the mere admixture of known substances without a synergistic effect. The appellant sought to patent compositions combining thermostable phytase variants with vitamins and minerals, arguing that these mixtures provided improved functionality in animal feed.

The Assistant Controller objected, stating that the compositions lacked synergy, as the combined ingredients functioned independently and did not produce a result greater than the sum of their individual effects. The Court agreed, noting that the appellant had not provided evidence to demonstrate how the combination created a novel or unexpected benefit.

By failing to establish a synergistic relationship among the ingredients, the composition claims fell within the exclusion under Section 3(e). The Court emphasized that without synergy, the mixture remains an aggregation of properties, which is insufficient to merit patent protection.

 

4. Do the compositions combining phytase variants with vitamins and minerals demonstrate synergy under Section 3(e)?

Synergy refers to the phenomenon where the combination of ingredients results in properties or effects that are greater than the sum of their individual contributions. The appellant argued that the inclusion of thermostable phytase variants with vitamins and minerals in animal feed improved bioavailability and stability.

However, the Court found no evidence to support this claim. The compositions did not exhibit any new or unexpected properties beyond those of the individual ingredients. The Assistant Controller’s position that the compositions were predictable and lacked inventiveness was upheld.

Without synergy, the Court concluded that the compositions could not be patented under Section 3(e). This reinforces the principle that merely combining known substances without a novel effect does not qualify for patent protection.

 

Judgment

The Madras High Court delivered a split judgment on Novozymes' appeal. It ruled that Section 3(d) could apply to biochemicals like phytase, and the enhanced thermostability of the phytase variants qualified as a significant enhancement of efficacy, making the variants patentable. However, under Section 3(e), the court upheld the rejection of claims 8–11, stating that they were merely admixtures of known ingredients (phytase, vitamins, and minerals) without demonstrating synergy or unexpected properties.

The court partially allowed the appeal: Claims 1–7 (related to the phytase variants) were deemed patentable, while claims 8–11 (composition claims) were rejected. The judgment clarified that improvements like thermostability can be considered enhancements of efficacy, while composition claims require synergy to be patentable under Section 3(e).[3]

 

Conclusion

In Novozymes v. Assistant Controller of Patents & Designs, the Madras High Court addressed key issues regarding Sections 3(d) and 3(e) of the Patents Act, 1970, in relation to biotechnological inventions. The court ruled in favor of Novozymes for the phytase variants, acknowledging that the enhanced thermostability of the enzyme constituted a significant enhancement of efficacy under Section 3(d), making the variants patentable. This decision broadens the interpretation of "efficacy," recognizing that industrial applications like thermostability, especially in animal feed, qualify as an enhancement of efficacy, even without improving enzymatic activity.

However, the court upheld the rejection of composition claims (claims 8–11) under Section 3(e), ruling that they were simply admixtures of known substances and lacked synergy. The decision emphasizes the strict criteria for composition claims, underscoring the need for evidence that the combination creates new or enhanced properties beyond the sum of the individual ingredients.

Ultimately, the judgment clarifies the patentability of biotechnological innovations in India, distinguishing between innovations that enhance industrial functionality and compositions that require novel interactions to be eligible for protection. This ruling marks an important step in aligning patent law with advancements in biotechnology.

 

 



[1] Novozymes v. Assistant Controller of Patents & Designs, CMA (PT) No. 33 of 2023, Indian Patent Application No. 5326/CHENP/2008 (Madras High Court 2023).

[2] Novozymes v. Assistant Controller of Patents & Designs, Legal Vidhiya (Oct. 10, 2023), Link.

[3] Madras High Court Verdict on Scope of Sections 3(d) and 3(e) of Patents Act, SCC Online (Oct. 10, 2023), Link

PUBLIC DOCUMENTS

Meaning Public documents are official records authenticated by public officers in their official capacity. These documents serve as reliab...